Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Biogen
The study is a double-blind, placebo-controlled study of BG00012 plus methotrexate, versus methotrexate alone, in patients with active RA, who have had an incomplete response to other conventional disease modifying anti-rheumatic (DMARD) therapy.
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
must be taking methotrexate
inadequate response to at least one conventional DMARD
swollen and tender joint count
You may not be if
previous treatment with TNF or any other biologic or prosorba column
